PRAECIS PHARMACEUTICALS is a biopharmaceutical company pioneering revolutionary new treatments for prostate cancer. The Company's lead drug candidate was synthesized and screened using its proprietary combinatorial chemistry and mass screening technology. Recent clinical trials data are extremely encouraging.

Founders: Kevin F. McLaughlin